[go: up one dir, main page]

AR063120A1 - Composiciones inyectables de deposito y proceso para prepararlas - Google Patents

Composiciones inyectables de deposito y proceso para prepararlas

Info

Publication number
AR063120A1
AR063120A1 ARP070104388A ARP070104388A AR063120A1 AR 063120 A1 AR063120 A1 AR 063120A1 AR P070104388 A ARP070104388 A AR P070104388A AR P070104388 A ARP070104388 A AR P070104388A AR 063120 A1 AR063120 A1 AR 063120A1
Authority
AR
Argentina
Prior art keywords
component
optionally
active agent
compositions
mixing
Prior art date
Application number
ARP070104388A
Other languages
English (en)
Inventor
Kour Chand Jindal
Sampath Kumar Devarajan
Rajesh Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR063120A1 publication Critical patent/AR063120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones inyectables de deposito que comprenden al menos un agente activo, opcionalmente con uno o.más excipientes farmacéuticamente aceptables en forma de un sistema de componentes multiples que comprende preferiblemente al menos dos componentes que, al ser suministrados a un individuo que los necesita, forma un deposito de gel in situ o implante en el lugar de la inyeccion tras el contacto con fluidos corporales y exhibe una liberacion prolongada del agente activo. Proceso para preparacion de tales composiciones y métodos para usar dichas composiciones. Reivindicacion 4: Una composicion tal como se reivindica en la reivindicacion 1, caracterizada porque el agente activo se selecciona de un grupo que comprende anastrozola, lentrozola, tamsulosin, donepezil, aripiprazol, olanzapina, risperidona y ziprasidona. Reivindicacion 25: Un proceso para la preparacion de una composicion inyectable tal como se reivindica en la reivindicacion 7, caracterizado por comprender los siguientes pasos: i) mezclar el agente(s) activo con polímero(s) biodegradable para formar micropartículas o nanopartículas, (ii) mezclas las micropartículas o nanopartículas del paso (i) opcionalmente con agente(s) mejoradotes de la viscosidad y/u opcionalmente con uno o más excipientes para formar el componente 1, (iii) mezclar el vehículo líquido opcionalmente con agente(s) mejorador(es) de la viscosidad y/u otros excipientes para formar el componente 2, y (iv) mezclar el componente 1 y el componente 2 para obtener el compuesto deseado antes de la administracion.
ARP070104388A 2006-10-05 2007-10-03 Composiciones inyectables de deposito y proceso para prepararlas AR063120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2195DE2006 2006-10-05

Publications (1)

Publication Number Publication Date
AR063120A1 true AR063120A1 (es) 2008-12-30

Family

ID=39268891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104388A AR063120A1 (es) 2006-10-05 2007-10-03 Composiciones inyectables de deposito y proceso para prepararlas

Country Status (17)

Country Link
US (2) US20100015195A1 (es)
EP (2) EP2086505A2 (es)
JP (2) JP2010505821A (es)
KR (2) KR20090087441A (es)
CN (2) CN101541313A (es)
AR (1) AR063120A1 (es)
AU (2) AU2007303794A1 (es)
BR (2) BRPI0718288A2 (es)
CA (2) CA2665105A1 (es)
CL (1) CL2007002851A1 (es)
EA (1) EA200970348A1 (es)
IL (2) IL197946A0 (es)
MA (2) MA30814B1 (es)
MX (2) MX2009003735A (es)
RU (1) RU2009116933A (es)
TN (2) TN2009000124A1 (es)
WO (2) WO2008041246A2 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
DK2526996T3 (da) 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulering til intrakutan injektion
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR20100023862A (ko) * 2007-06-22 2010-03-04 싸이도우스 엘엘씨. 트윈 80을 함유하지 않은 도세탁셀의 용해 제제
CA2691597C (en) * 2007-06-25 2016-04-05 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2716576A1 (en) 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101569622B (zh) * 2008-04-30 2012-11-21 天津药物研究院 一种用于注射给药的药物制剂及其制备方法
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
SMT202000405T1 (it) * 2008-09-04 2020-09-10 Amylin Pharmaceuticals Llc Formulazioni a rilascio prolungato usando veicolanti non acquosi
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
EP2403483B1 (en) 2009-03-02 2017-05-10 Assistance Publique Hôpitaux De Paris Injectable biomaterial
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
AU2010249683B2 (en) 2009-05-18 2015-06-25 Glaukos Corporation Drug eluting ocular implant
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CN101669942A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 难溶性药物组合物
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
ES2654147T3 (es) 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
JP5977225B2 (ja) * 2010-03-15 2016-08-24 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． 成長ホルモン分泌促進物質受容体リガンドの医薬組成物
ES2655592T3 (es) * 2010-03-29 2018-02-20 Evonik Corporation Composiciones y métodos para la retención mejorada de una composición farmacéutica en un sitio de administración local
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
SG184879A1 (en) * 2010-08-24 2012-11-29 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
CA2816203C (en) * 2010-10-28 2017-02-21 Transdermal Research Pharm Laboratories, Llc Aripiprazole compositions and methods for its transdermal delivery
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG193389A1 (en) 2011-03-10 2013-10-30 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs
HUE032109T2 (en) * 2011-03-18 2017-08-28 Alkermes Pharma Ireland Ltd Injectable pharmaceutical compositions containing water insoluble antipsychotic, sorbitan laurate and polysorbate 20
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
US9949928B2 (en) * 2013-05-01 2018-04-24 The Regents Of The University Of Colorado, A Body Corporate Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
US20160200891A1 (en) * 2013-08-22 2016-07-14 Polyvalor Limited Partnership Porous gels and methods for their preparation
JP2015093854A (ja) * 2013-11-12 2015-05-18 株式会社クレハ 水性組成物および加水分解抑制方法
CH708890B1 (de) * 2013-11-22 2018-03-15 Sandel Thomas Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät.
US20150174254A1 (en) 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP6982495B2 (ja) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド ペーストの皮内および／または皮下注射のためのシリンジ、キット、および方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2967195A1 (en) * 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017083717A1 (en) * 2015-11-11 2017-05-18 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US20190380967A1 (en) * 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CN106822039A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 水难溶或微溶性药物缓释组合物及其制备方法
CN106727422B (zh) * 2017-03-09 2018-10-02 王秋玉 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
IL272924B2 (en) 2017-09-11 2024-01-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7344197B2 (ja) * 2017-09-15 2023-09-13 オクラー リミテッド 眼科用送達装置
ES2989170T3 (es) * 2018-03-23 2024-11-25 Pharmajor Int Métodos no hormonales para la anticoncepción masculina que comprenden (R)-silodosina
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
MA53291A (fr) * 2018-08-10 2022-05-11 Ephemeral Solutions Inc Particules contenant des agents colorants et procédés pour les utiliser
EP3988139A4 (en) * 2019-06-21 2023-07-19 Korea University Research and Business Foundation In vivo bulking agent, injection comprising same, and preparation method therefor
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
KR20230052921A (ko) * 2020-08-17 2023-04-20 휴먼웰 파마슈티컬 유에스 지속성 인-시투(in-situ) 형성/겔화 조성물
CN111956599B (zh) * 2020-09-29 2023-02-17 江苏集萃新型药物制剂技术研究所有限公司 皮下植入药剂及其组合物和制备方法
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
EP4527389A1 (en) 2022-05-18 2025-03-26 Laboratorios Farmacéuticos Rovi S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors
WO2024151625A1 (en) * 2023-01-10 2024-07-18 Georgetown University Non-toxic plga compositions and methods of making and using same
CN116850146B (zh) * 2023-05-22 2024-05-14 济南大学 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CA2435415A1 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
EP1450766B1 (fr) * 2001-10-10 2015-04-22 Pierre Fabre Medicament Microspheres biodegradables a liberation prolongee et leur procede de preparation
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
CA2665105A1 (en) 2008-04-10
EP2089000A2 (en) 2009-08-19
EP2086505A2 (en) 2009-08-12
JP2010505819A (ja) 2010-02-25
IL197946A0 (en) 2009-12-24
CN101541316A (zh) 2009-09-23
US20100098735A1 (en) 2010-04-22
WO2008041245A3 (en) 2008-05-22
WO2008041245A2 (en) 2008-04-10
JP2010505821A (ja) 2010-02-25
RU2009116933A (ru) 2010-11-10
CL2007002851A1 (es) 2008-01-18
WO2008041246A2 (en) 2008-04-10
AU2007303794A1 (en) 2008-04-10
MA30817B1 (fr) 2009-10-01
US20100015195A1 (en) 2010-01-21
AU2007303793A1 (en) 2008-04-10
TN2009000125A1 (en) 2010-10-18
KR20090087441A (ko) 2009-08-17
MA30814B1 (fr) 2009-10-01
IL197947A0 (en) 2009-12-24
KR20090094811A (ko) 2009-09-08
CN101541313A (zh) 2009-09-23
MX2009003737A (es) 2009-06-16
CA2665101A1 (en) 2008-04-10
MX2009003735A (es) 2009-04-22
TN2009000124A1 (en) 2010-10-18
BRPI0720346A2 (pt) 2014-06-24
BRPI0718288A2 (pt) 2013-11-19
WO2008041246A3 (en) 2008-05-29
EA200970348A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
AR063120A1 (es) Composiciones inyectables de deposito y proceso para prepararlas
AR070033A1 (es) Composiciones inyectables, sus procesos y usos
NZ604342A (en) Antipsychotic injectable depot composition
SI2579874T1 (en) INJECTION LIQUID COMPONENTS, EXPLOSIVE BUPRENORPHIN
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
AR041913A1 (es) Formulaciones de deposito de liberacion controlada
JP2013533230A5 (es)
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
PE20060003A1 (es) Formulacion farmaceutica polimerica para moldear por inyeccion
MX359119B (es) Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas.
Zhang et al. A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides
AR113096A1 (es) Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
HK1220628A1 (zh) 包含高粘度液体载体的可注射控制释放组合物
NZ627368A (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
BR112015021709B8 (pt) Poli(beta-amino ésteres) modificados para administração de fármacos e nanopartícula compreendendo os mesmos, uma composição compreendendo os mesmos, método de encapsulamento de um agente em uma matriz de polímeros para formar nanopartículas, e uso dos poli(beta-amino ésteres)
HRP20161138T1 (hr) Farmaceutski pripravak za oralnu primjenu
BR112014029209A2 (pt) formulação para implante de risperidona ou paliperidona
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
WO2007111945A3 (en) Method for management of diarrhea
JP2018510894A5 (es)
AR107212A1 (es) Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure